Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Period	Debt/Equity
2019-03-31	0.12
2020-03-31	0.27
2021-03-31	0.09
2022-03-31	0.12
2023-03-31	0.16
2024-03-31	0.30
2025-03-31	0.33

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REPL	$6.08	-22.05%	4.67M
3
4
5

Replimune Group Inc. (REPL) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Replimune Group Inc. Data in Excel

More REPL Financial Data